查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589176

皮質類固醇治療市場：按類型、給藥途徑和應用分類 - 2025-2030 年全球預測

Corticosteroids Therapy Market by Type (Glucocorticoids, Mineralocorticoids), Route of Administration (Inhaled, Oral, Systemic), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年皮質類固醇治療市值為49.7億美元，預計到2024年將達到52.6億美元，複合年成長率為7.48%，預計到2030年將達到82.4億美元。

皮質類固醇療法使用模仿皮質醇（腎上腺皮質自然分泌的荷爾蒙）的合成藥物來減少發炎並抑制免疫系統。皮質類固醇對於治療關節炎、過敏反應、氣喘、自體免疫疾病，甚至某些癌症等許多疾病至關重要，這表明它們在醫療干預中的必要性。這些藥物可局部、局部或靜脈注射，最終用途主要在醫療機構，如醫院和診所、製藥公司和研究型大學。市場成長要素包括慢性病盛行率上升、對自體免疫疾病的認知不斷提高以及藥物傳遞系統的進步。此外，擴大新興國家的醫療基礎設施也帶來了利潤豐厚的機會。然而，感染風險增加和潛在副作用（例如長期使用導致骨質疏鬆）、監管挑戰和抗藥性開拓等挑戰可能會阻礙市場成長。為了利用這些機會，公司應該專注於開發具有改進的安全性和個人化醫療方法的皮質類固醇。新型藥物輸送系統（例如吸入器和經皮吸收貼片）的創新有可能提高療效並最大限度地減少副作用。此外，皮質類固醇非基因組途徑的研究可能為創新治療鋪路。與研究機構的策略聯盟可以豐富產品平臺並加速進展。您還可以透過監控法規變更並敏捷地回應合規性來獲得競爭優勢。皮質類固醇治療市場充滿活力，與醫療保健政策和科學創新的波動密切相關。公司需要在研發方面採取積極主動的方法，專注於基因對齊治療方法，並利用數位健康技術來支持個人化治療策略。透過有效克服挑戰並抓住對客製化醫療保健解決方案不斷成長的需求，公司可以在這個不斷發展的市場中維持和擴大成長。

主要市場統計
基準年[2023] 49.7億美元
預測年份 [2024] 52.6億美元
預測年份 [2030] 82.4億美元
複合年成長率（%） 7.48%

市場動態：快速發展的皮質類固醇治療市場的關鍵市場洞察

供需的動態交互作用正在改變皮質類固醇治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 發炎和自體免疫疾病的盛行率增加
    • 藥物傳輸系統的可用性提高了便利性和有效性
    • 皮質類固醇在感染疾病治療的應用
  • 市場限制因素
    • 替代治療的可用性
  • 市場機會
    • 介紹一種新型可注射載體皮質類固醇療法
    • 改善單吸入性皮質類固醇治療
  • 市場挑戰
    • 與皮質類固醇治療相關的副作用

波特的五力：駕馭皮質類固醇治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解皮質類固醇治療市場的外部影響

外部宏觀環境因素在塑造皮質類固醇治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解皮質類固醇治療市場的競爭格局

對皮質類固醇治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣皮質類固醇治療市場供應商的績效評估

FPNV定位矩陣是評估皮質類固醇治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了皮質類固醇治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，皮質類固醇治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 發炎和自體免疫疾病的盛行率增加
      • 藥物傳輸系統的可用性提高了便利性和有效性
      • 皮質類固醇療法在感染疾病的治療應用
    • 抑制因素
      • 替代治療的可用性
    • 機會
      • 介紹一種新型可注射載體皮質類固醇療法
      • 改善單藥吸入類固醇治療
    • 任務
      • 與皮質類固醇治療相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章皮質類固醇治療市場：依類型

  • 糖皮質激素
  • 鹽皮質激素

第7章皮質類固醇治療市場：依給藥途徑

  • 吸入
  • 口服
  • 系統性的
  • 話題

第8章皮質類固醇治療市場：依應用分類

  • 急性呼吸道疾病
  • 內分泌學
  • 胃腸病學
  • 風濕病學
  • 皮膚過敏

第9章美洲皮質類固醇治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太皮質類固醇治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的皮質類固醇治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Allergan PLC by AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Galderma Group
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SANTHERA PHARMACEUTICALS
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C9976A

The Corticosteroids Therapy Market was valued at USD 4.97 billion in 2023, expected to reach USD 5.26 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 8.24 billion by 2030.

Corticosteroid therapy involves using synthetic drugs that mimic cortisol-a hormone naturally produced by the adrenal cortex, to reduce inflammation and suppress the immune system. They are critical in treating numerous conditions like arthritis, allergic reactions, asthma, autoimmune disorders, and even certain cancers, underscoring their necessity in medical interventions. These drugs are applied topically, orally, or intravenously and find end-use primarily in healthcare institutions such as hospitals and clinics, pharmaceuticals, and research universities. Market growth factors include the rising prevalence of chronic diseases, increasing awareness about autoimmune diseases, and advancements in drug delivery systems. Furthermore, expansions in healthcare infrastructure in emerging economies present lucrative opportunities. However, challenges such as potential side effects, like increased risk of infection and weakening of bones upon prolonged use, regulatory challenges, and the development of drug resistance may impede market growth. To capitalize on these opportunities, businesses should focus on developing corticosteroids with improved safety profiles and personalized medicine approaches. Innovations in novel drug delivery systems, like inhalers or transdermal patches, could enhance efficacy and minimize side effects. Furthermore, research into non-genomic pathways of corticosteroids could pave the way for innovative therapies. Strategic collaborations with research institutions could enrich product pipelines and accelerate advancements. Monitoring regulatory changes and being agile in compliance can also provide competitive advantages. The corticosteroid therapy market is dynamic, closely tied to fluctuations in healthcare policies and scientific innovations. Companies need to adopt a proactive approach in research and development, focusing on genetically aligned treatments and leveraging digital health technologies to support personalized therapeutic strategies. By effectively navigating the challenges and tapping into the growing demand for tailored healthcare solutions, companies can sustain growth and expand within this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 4.97 billion
Estimated Year [2024] USD 5.26 billion
Forecast Year [2030] USD 8.24 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Corticosteroids Therapy Market

The Corticosteroids Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of inflammatory and autoimmune diseases
    • Availability of drug delivery systems with improved convenience and efficacy
    • Therapeutic applications of corticosteroids-therapy in infectious diseases
  • Market Restraints
    • Availability of alternative therapies
  • Market Opportunities
    • Introduction of novel injectable carrier-based corticosteroid therapy
    • Improvements in single-entity inhaled corticosteroid therapy
  • Market Challenges
    • Adverse effects associated with corticosteroids-therapy

Porter's Five Forces: A Strategic Tool for Navigating the Corticosteroids Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Corticosteroids Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Corticosteroids Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Corticosteroids Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Corticosteroids Therapy Market

A detailed market share analysis in the Corticosteroids Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Corticosteroids Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Corticosteroids Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Corticosteroids Therapy Market

A strategic analysis of the Corticosteroids Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Corticosteroids Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan PLC by AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Galderma Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., SANTHERA PHARMACEUTICALS, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Corticosteroids Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Glucocorticoids and Mineralocorticoids.
  • Based on Route of Administration, market is studied across Inhaled, Oral, Systemic, and Topical.
  • Based on Application, market is studied across Acute Respiratory Diseases, Endocrinology, Gastroenterology, Rheumatology, and Skin Allergies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of inflammatory and autoimmune diseases
      • 5.1.1.2. Availability of drug delivery systems with improved convenience and efficacy
      • 5.1.1.3. Therapeutic applications of corticosteroids-therapy in infectious diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel injectable carrier-based corticosteroid therapy
      • 5.1.3.2. Improvements in single-entity inhaled corticosteroid therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with corticosteroids-therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Corticosteroids Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Glucocorticoids
  • 6.3. Mineralocorticoids

7. Corticosteroids Therapy Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhaled
  • 7.3. Oral
  • 7.4. Systemic
  • 7.5. Topical

8. Corticosteroids Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Respiratory Diseases
  • 8.3. Endocrinology
  • 8.4. Gastroenterology
  • 8.5. Rheumatology
  • 8.6. Skin Allergies

9. Americas Corticosteroids Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Corticosteroids Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Corticosteroids Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan PLC by AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Biogen Inc.
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Inc.
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. Galderma Group
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Lupin Pharmaceuticals, Inc.
  • 15. Merck & Co., Inc.
  • 16. Mylan N.V.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. SANTHERA PHARMACEUTICALS
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CORTICOSTEROIDS THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CORTICOSTEROIDS THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CORTICOSTEROIDS THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY MINERALOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ACUTE RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SKIN ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023